Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Last trade$16.07
Day change-$0.635 (-3.80%)
Day range$15.92 – $17.89
Volume1,360,464
Market cap$3.13B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.13B
Price / earnings
—
Price / book
3.36×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.95×
Profitability
Earnings per share
-$3.23
Return on assets
-48.99%
Return on equity
-64.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.24×
Current ratio
12.99×
Quick ratio
12.99×
Cash ratio
10.09×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$568.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DYN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$35.33M
$29.49M
$24.39M
$20.7M
$16.67M
$16.56M
$15.93M
$15.3M
Research and development
$161.74M
$152.17M
$100.89M
$95.43M
$97.22M
$99.24M
$106.45M
$81.81M
Total operating expenses
$197.37M
$181.66M
$125.28M
$116.13M
$113.61M
$115.79M
$122.37M
$97.11M
Operating income
-$197.37M
-$181.66M
-$125.28M
-$116.13M
-$113.61M
-$115.79M
-$122.37M
-$97.11M
Interest expense
-$5.95M
-$4.6M
-$4.2M
-$3.19M
-$2.9M
-$94K
$0
$0
Income before taxes
-$193.55M
-$178.56M
-$120.85M
-$111.96M
-$108.04M
-$110.86M
-$115.36M
-$89.54M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$193.55M
-$178.56M
-$120.85M
-$111.96M
-$108.04M
-$110.86M
-$115.36M
-$89.54M
Net income attributable to common shareholders
-$193.55M
-$178.56M
-$120.85M
-$111.96M
-$108.04M
-$110.86M
-$115.36M
-$89.54M
EBITDA
-$196.73M
-$181.1M
-$124.73M
-$115.61M
-$113.09M
-$115.29M
-$121.87M
-$96.66M
Basic earnings per share
-$1.06
-$1.08
-$0.73
-$0.76
-$0.76
-$0.97
-$1.05
-$0.88
Diluted earnings per share
-$1.06
-$1.08
-$0.73
-$0.76
-$0.76
-$0.97
-$1.05
-$0.88
Recent news
Company coverage with links to the original publishers.
Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, generating gross proceeds of approximately $375.2 million. The offering is expected to close on July 23, 2026, with underwriters granted a 30-day option to purchase an additional 2.745 million shares. Morgan Stanley, Jefferies, and Evercore ISI are serving as joint book-running managers.
Dyne Therapeutics, a clinical-stage neuromuscular disease company, announced a $300 million underwritten public offering of common stock with a 30-day option for underwriters to purchase an additional $45 million. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint book-running managers. The offering is subject to market conditions and SEC approval.
The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recommends Viking due to the substantially larger market opportunity in obesity treatment, despite competitive pressures from industry giants like Eli Lilly and Novo Nordisk.
FCPM III Services B.V. reduced its Dyne Therapeutics position by 818,460 shares ($14.11 million) in May 2026, though the fund maintains Dyne as its second-largest holding at 11.8% of assets. Despite the partial exit, the stake reduction appears strategic rather than a loss of conviction, as Dyne shares have surged 56% over the past year. The company recently submitted a Biologics License Application for its lead Duchenne muscular dystrophy therapy z-rostudirsen, targeting potential FDA approval and U.S. launch in Q1 2027.
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.